Oculis has announced the appointment of Björn Tackenberg, M.D., Ph.D., as its new Chief Scientific Officer. He will lead the company's global scientific strategy and expand its research portfolio, focusing on the development of Privosegtor.
Who to call at Oculis Holding AG, and when
A new leader at Oculis Holding AG brings new priorities and often new vendors. The first weeks are when they listen.
An alert the day Oculis Holding AG raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Oculis Holding AG, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Oculis Holding AG. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Oculis Holding AG
Location
Lausanne, Vaud, Switzerland
About
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. The company is focused on advancing late-stage clinical trials for treating conditions such as Dry Eye Disease (DED) and Diabetic Macular Edema (DME).
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Oculis Holding AG changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
LausanneBiotechnologyHealth CareTherapeuticsBiopharma